PharmGen Science, Inc. (KRX:004720)

PharmGen Science Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	171,287	166,779	150,931	109,866	96,614
Other Revenue	-0	-	-	-0	-
Revenue	171,287	166,779	150,931	109,866	96,614
Revenue Growth (YoY)	2.70%	10.50%	37.38%	13.72%	1.55%
Cost of Revenue	63,413	69,029	69,857	49,136	43,085
Gross Profit	107,874	97,749	81,073	60,730	53,529
Selling, General & Admin	90,112	81,752	69,089	61,822	50,270
Research & Development	4,402	5,118	2,886	2,270	1,115
Other Operating Expenses	163.82	206.93	203.02	175.86	109.92
Operating Expenses	97,248	88,623	73,662	65,668	55,434
Operating Income	10,626	9,127	7,412	-4,938	-1,905
Interest Expense	-4,157	-4,264	-3,509	-1,721	-289.55
Interest & Investment Income	100	98.41	66.04	87.8	119.67
Earnings From Equity Investments	-4,916	-2,539	87,213	46,633	14,508
Currency Exchange Gain (Loss)	2.13	217.94	13.97	0.2	-24.05
Other Non Operating Income (Expenses)	2,440	5,938	-1,115	2,699	-31.05
EBT Excluding Unusual Items	4,095	8,579	90,081	42,760	12,378
Gain (Loss) on Sale of Investments	-3,061	51.6	9.77	1.11	-1,085
Gain (Loss) on Sale of Assets	-16.83	46.35	2.94	-11.49	-29.13
Asset Writedown	-	-228.3	-133.08	-799.9	-53.75
Pretax Income	1,017	8,448	89,960	41,949	11,209
Income Tax Expense	-1,773	2,361	19,902	9,535	2,085
Earnings From Continuing Operations	2,790	6,088	70,058	32,414	9,124
Minority Interest in Earnings	1.05	1.04	1.48	51.54	98.12
Net Income	2,791	6,089	70,060	32,466	9,222
Net Income to Common	2,791	6,089	70,060	32,466	9,222
Net Income Growth	-54.16%	-91.31%	115.79%	252.04%	2953.92%
Shares Outstanding (Basic)	18	16	16	15	14
Shares Outstanding (Diluted)	22	21	22	19	15
Shares Change (YoY)	4.74%	-3.68%	16.09%	23.81%	30.15%
EPS (Basic)	153.88	374.22	4498.10	2206.02	674.98
EPS (Diluted)	152.25	323.65	3369.29	1814.33	623.34
EPS Growth	-52.96%	-90.39%	85.70%	191.07%	2297.46%
Free Cash Flow	1,466	3,173	-11,208	-22,966	-1,664
Free Cash Flow Per Share	67.29	152.58	-519.12	-1234.84	-110.74
Gross Margin	62.98%	58.61%	53.72%	55.28%	55.41%
Operating Margin	6.20%	5.47%	4.91%	-4.49%	-1.97%
Profit Margin	1.63%	3.65%	46.42%	29.55%	9.54%
Free Cash Flow Margin	0.86%	1.90%	-7.43%	-20.90%	-1.72%
EBITDA	15,262	13,374	10,783	-1,796	1,057
EBITDA Margin	8.91%	8.02%	7.14%	-1.64%	1.09%
D&A For EBITDA	4,636	4,247	3,371	3,142	2,963
EBIT	10,626	9,127	7,412	-4,938	-1,905
EBIT Margin	6.20%	5.47%	4.91%	-4.49%	-1.97%
Effective Tax Rate	-	27.94%	22.12%	22.73%	18.60%
Advertising Expenses	2,284	2,345	2,833	2,168	1,853

Source: S&P Global Market Intelligence. Standard template. Financial Sources.